TMTP1-ICG Mapping in Laparoscopic SLN Detection in Cervical Cancer

Study Overview
=================
Brief Summary
-----------------
investigators aimed to determine the validity of our novel tumor targeted fluorescent TMTP1-ICG to increased accuracy of laparoscopic SLN mapping

Official Title
-----------------
Novel Tumor Targeted Fluorescent TMTP1-ICG Mapping in Laparoscopic Sentinel Lymph Node Detection in Cervical Cancer Patients

Conditions
-----------------
Cervical Cancer

Intervention / Treatment
-----------------
* Drug: TMTP1-ICG
* Drug: ICG


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: At least 18 years of age, married, without childbearing requirements at the time of consent. FIGO stage IA1-IIB cervical squamous cell cancer and is a candidate for laparoscopy intervention, with lymph node dissection being a part of the surgical plan. Subject has provided written informed consent. Exclusion Criteria: Breast-feeding or pregnant Ongoing participation in another clinical trial with an investigational drug with 3 months Own allergy towards ICG and/or alcohol Diagnosis of bacterial vaginosis, fungal vaginitis, sexually transmitted diseases Patients with cardiac dysfunction or hepatic insufficiency or renal insufficiency

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: TMTP1<br>The TMTP1-ICG (WuXi AppTec, Shanghai, China) powder was diluted in 20 ml of aqueous sterile water to a concentration of 1.0 mg/mL. 0.4ml of this TMTP1-ICG solution was injected into the cervix, divided into 3 and 9 o'clock position, in the operating room. During the laparoscopy, the PinPoint S1 Novadaq (PinPoint Endoscopic Fluorescence Imaging System, NOVADAQ, Mississauga, ON, Canada), 30° laparoscopes were used for fluorescent detection. | Drug: TMTP1-ICG<br>* Detection of SLN<br>|
| Active Comparator: ICG<br>The ICG powder was diluted in 20 ml of aqueous sterile water to a concentration of 1.0 mg/mL. 0.4ml of ICG solution was injected into the cervix, divided into 3 and 9 o'clock position, in the operating room. During the laparoscopy, the PinPoint S1 Novadaq (PinPoint Endoscopic Fluorescence Imaging System, NOVADAQ, Mississauga, ON, Canada), 30° laparoscopes were used for fluorescent detection. | Drug: ICG<br>* Detection of SLN<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Detection rate of sentinel lymph node | Detection of sentinel lymph node per patient | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sensitivity | Sensitivity of SLN mapping of TMTP1-ICG compared to the sensitivity of SLN mapping of ICG | 7 days | 
| Specificity | Specificity of SLN mapping of TMTP1-ICG compared to the sensitivity of SLN mapping of ICG | 7 days | 
| Incidence of adverse events |  | 7 days |